WallStSmart

Abbott Laboratories (ABT)vsKoninklijke Philips NV ADR (PHG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 149% more annual revenue ($44.33B vs $17.83B). ABT leads profitability with a 14.7% profit margin vs 5.0%. PHG appears more attractively valued with a PEG of 0.36. ABT earns a higher WallStSmart Score of 51/100 (C-).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

PHG

Hold

49

out of 100

Grade: D+

Growth: 5.3Profit: 5.0Value: 7.3Quality: 5.3
Piotroski: 6/9Altman Z: 1.47
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-323.7%)

Margin of Safety

-323.7%

Fair Value

$25.30

Current Price

$105.46

$80.16 premium

UndervaluedFair: $25.30Overvalued
PHGSignificantly Overvalued (-340.5%)

Margin of Safety

-340.5%

Fair Value

$7.28

Current Price

$26.25

$18.97 premium

UndervaluedFair: $7.28Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$191.06B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

PHG4 strengths · Avg: 9.0/10
PEG RatioValuation
0.3610/10

Growing faster than its price suggests

Revenue GrowthGrowth
110.0%10/10

Revenue surging 110.0% year-over-year

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$1.31B8/10

Generating 1.3B in free cash flow

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.564/10

Expensive relative to growth rate

P/E RatioValuation
29.6x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PHG4 concerns · Avg: 3.0/10
P/E RatioValuation
26.4x4/10

Moderate valuation

Return on EquityProfitability
7.8%3/10

ROE of 7.8% — below average capital efficiency

Profit MarginProfitability
5.0%3/10

5.0% margin — thin

EPS GrowthGrowth
-50.0%2/10

Earnings declined 50.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : PHG

The strongest argument for PHG centers on PEG Ratio, Revenue Growth, Price/Book. Revenue growth of 110.0% demonstrates continued momentum. PEG of 0.36 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : PHG

The primary concerns for PHG are P/E Ratio, Return on Equity, Profit Margin.

Key Dynamics to Monitor

ABT profiles as a value stock while PHG is a hypergrowth play — different risk/reward profiles.

PHG carries more volatility with a beta of 0.94 — expect wider price swings.

PHG is growing revenue faster at 110.0% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Bottom Line

ABT scores higher overall (51/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Koninklijke Philips NV ADR

HEALTHCARE · MEDICAL DEVICES · USA

Koninklijke Philips NV is a healthcare technology company in North America, Greater China and internationally. The company is headquartered in Amsterdam, the Netherlands.

Want to dig deeper into these stocks?